Communiqués SpectraCure AB

Actions

SPEC

SE0007158118

Equipement et technologie médicale avancés

PEA

Temps Différé Nasdaq Stockholm 16:04:02 04/09/2026			Varia. 5j.	Varia. 1 janv.
0,0235 ^SEK	-1,67 %		-6,00 %	-84,92 %

31/08	Onze actions ont atteint un nouveau plus bas de 52 semaines aujourd'hui à la Bourse de Stockholm	FW
28/08	11 actions ont atteint un nouveau plus bas sur 52 semaines aujourd'hui à la Bourse de Stockholm	FW

Communiqués

01/12	SpectraCure : Interview with CEO Johannes Swartling and Jörgen Wennberg, Chairman of the Board	PU
23/02/24	SpectraCure takes the next step in the work with the new clinical study	AQ
23/01/24	A well-accomplished annual audit in accordance with ISO 13485:2016	AQ
19/12/23	Expert group comments on results of ongoing study	AQ
29/11/23	SpectraCure : Masoud Khayyami presents SpectraCure at investor meetingon November 5 in Lund!	PU
16/11/23	SpectraCure has decided to seek approval for a clinical study of primary prostate cancer	AQ
31/10/23	SpectraCure : Meet SpectraCure’s board member, Homer Pien!	PU
06/10/23	SpectraCure strengthens presence among urologists	AQ
27/06/23	SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®	AQ
07/12/22	SpectraCures signs Letter of Intent with Cheplapharm	AQ
25/11/22	SpectraCure : First treatment with Q-PRO and integrated image management technology	PU
23/11/22	SpectraCure : Skåne University Hospital in Malmö is included in the clinical trial for treatment of recurrent prostate cancer	PU
19/09/22	SpectraCure : new treatment system has been approved in the UK for use in clinical trials	PU
30/08/22	Patent regarding the new generation of treatment systems approved in Europe	AQ
20/06/22	SpectraCure : Software for improved imaging technology is approved for use in clinical study in the US	PU
07/06/22	SpectraCure has been approved a grant from EU of € 125,000	AQ
03/06/22	SpectraCure : Patent approved in Europe	PU
16/05/22	A new Board has been installed at SpectraCure	AQ
12/07/21	SpectraCure : Investor Letter July 2021	PU
15/04/21	SpectraCure : The Nomination Committee's proposal for election of board members in SpectraCure AB	AQ
05/03/21	SpectraCure : Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer	AQ
21/10/20	SpectraCure : NeoDynamics carries out directed new share issue of approximately SEK 90 million and convenes extraordinary general meeting	AQ
16/09/20	SpectraCure : Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!	AQ
26/06/20	SpectraCure publ : raises approximately SEK 140 million through a fully subscribed rights issue	AQ
07/04/20	SpectraCure publ : Patent application enters PCT phase, SpectraCure ensures development and work	AQ